Exelixis, Inc. (NASDAQ:EXEL) EVP Dana Aftab Sells 96,986 Shares

Exelixis, Inc. (NASDAQ:EXEL) EVP Dana Aftab sold 96,986 shares of the business’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $35.00, for a total transaction of $3,394,510.00. Following the completion of the transaction, the executive vice president now owns 498,945 shares of the company’s stock, valued at approximately $17,463,075. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Dana Aftab also recently made the following trade(s):

• On Wednesday, October 30th, Dana Aftab sold 1,162 shares of Exelixis stock. The stock was sold at an average price of $31.40, for a total transaction of $36,486.80.
• On Monday, August 12th, Dana Aftab sold 20,883 shares of Exelixis stock. The shares were sold at an average price of $27.06, for a total transaction of $565,093.98.

Exelixis Trading Up 0.8 %

NASDAQ EXEL traded up $0.29 on Thursday, hitting $35.80. 1,764,453 shares of the company’s stock were exchanged, compared to its average volume of 2,076,657. The stock has a market cap of $10.22 billion, a price-to-earnings ratio of 22.76, a P/E/G ratio of 0.87 and a beta of 0.51. Exelixis, Inc. has a 52 week low of $19.20 and a 52 week high of $36.17. The stock has a 50-day moving average of $27.67 and a 200-day moving average of $24.56.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share for the quarter, beating analysts’ consensus estimates of $0.36 by $0.04. Exelixis had a net margin of 22.43% and a return on equity of 20.99%. The business had revenue of $539.50 million during the quarter, compared to the consensus estimate of $490.31 million. During the same quarter last year, the firm earned $0.10 earnings per share. The business’s revenue for the quarter was up 14.3% on a year-over-year basis. As a group, analysts predict that Exelixis, Inc. will post 1.68 earnings per share for the current year.

Institutional Trading of Exelixis

Several institutional investors and hedge funds have recently bought and sold shares of EXEL. LSV Asset Management increased its holdings in Exelixis by 107.7% in the second quarter. LSV Asset Management now owns 5,763,728 shares of the biotechnology company’s stock worth $129,511,000 after buying an additional 2,989,021 shares during the last quarter. Jupiter Asset Management Ltd. raised its stake in Exelixis by 148.2% during the first quarter. Jupiter Asset Management Ltd. now owns 2,267,894 shares of the biotechnology company’s stock worth $53,817,000 after acquiring an additional 1,354,062 shares in the last quarter. Los Angeles Capital Management LLC boosted its holdings in shares of Exelixis by 124.0% during the 3rd quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock worth $46,473,000 after buying an additional 991,494 shares in the last quarter. Swedbank AB bought a new position in Exelixis in the 1st quarter valued at $22,455,000. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in shares of Exelixis in the 1st quarter valued at about $10,906,000. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Analyst Ratings Changes

EXEL has been the topic of several recent analyst reports. TD Cowen lifted their price objective on shares of Exelixis from $27.00 to $34.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Morgan Stanley lifted their price target on Exelixis from $26.00 to $28.00 and gave the stock an “equal weight” rating in a research note on Friday, October 11th. Stifel Nicolaus raised their price objective on Exelixis from $26.00 to $30.00 and gave the stock a “hold” rating in a research note on Wednesday, October 16th. StockNews.com raised Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 13th. Finally, Piper Sandler increased their price target on Exelixis from $33.00 to $36.00 and gave the company an “overweight” rating in a report on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $31.44.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.